

## Confirmed Speakers

### EFMC Award Lectures

#### **Prous Institute - Overton and Meyer Award for New Technologies in Drug Discovery Award Lecture**

Prof. Alessio CIULLI  
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

#### **Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology Award Lecture**

Prof. Herbert WALDMANN  
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)

#### **UCB Ehrlich Award for Excellence in Medicinal Chemistry Award Lecture**

Prof. Mike WARING  
(UNIVERSITY OF NEWCASTLE, Newcastle upon Tyne, United Kingdom)

### Plenary Speakers

#### **Discovery of Lead Compounds and Drug Candidates : Opportunities Unique to the World of Small Molecules**

Prof. Benoit DEPREZ  
(INSTITUT PASTEUR DE LILLE, Lille, France)

#### **New Biology and Therapeutic Approaches from RNA Shape and Modification**

Prof. Eric MISKA  
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

#### **Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire**

Prof. Sarah E. REISMAN  
(CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, United States)

#### **Title to be announced**

Prof. Outi VAARALA  
(ORION CORPORATION, Espoo, Finland)

### Invited Speakers

#### **De Novo Cyclic Peptides as Chemical Tools to Explore Epigenetic Regulation**

&nbsp;(SANOFI-AVENTIS DEUTSCHLAND GMBH)

Dr Louise WALPORT&nbsp;(THE FRANCIS CRICK INSTITUTE, London, United Kingdom)

#### **Current Challenges in Antiviral Therapies Against Coronaviruses and Other Emerging RNA Viruses**

Dr Karine ALVAREZ  
(AIX-MARSEILLE UNIVERSITY, Marseille, France)

#### **Fragment-Based Approaches to Stabilize Protein-Protein Interactions**

Prof. Michelle ARKIN  
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

#### **Embrace Complexity: in Silico Polypharmacological Profiling to Repurpose Medicines and Design New Drugs**

Dr Andrea BECCARI  
(DOMPÉ PHARMA, L'Aquila, Italy)

#### **Inhibiting the MYC Oncogene through Cell Active Max-E47 (ME-47)**

## Confirmed Speakers

Dr Amy BITTNER MCCRACKEN  
(MERCK & CO, New Jersey, United States)

### **Molecular Vending Machines for the On-Demand Synthesis of Drug-Like Molecules**

Prof. Jeffrey BODE  
(ETH ZÜRICH, Zürich, Switzerland)

### **Discovery of Novel Kinase Inhibitors Through in Silico Fragment-Based Ligand Screening**

Prof. Pascal BONNET  
(UNIVERSITY OF ORLÉANS, Orléans, France)

### **Discovery of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Autism, Down Syndrome, and Brain Disorders with Defective NKCC1/KCC2 Ratio**

Dr Marco BORGOGNO  
(IAMA THERAPEUTICS SRL, Genoa, Italy)

### **A DNA Barcode with Enhanced Chemical Stability for DNA-encoded Library Design**

Dr Andreas BRUNSCHWEIGER  
(TU DORTMUND, Dortmund, Germany)

### **Medicinal Chemistry in the Development of Molecular Imaging Probes Targeting Prostate-Specific Membrane Antigen**

Prof. Youngjoo BYUN  
(KOREA UNIVERSITY, Sejong, Korea, South)

### **Fundamental Basis for SMN2 Specific Splicing Correction by Small Molecules and Bulge Repair Mechanism**

Dr Sébastien CAMPAGNE  
(INSERM BORDEAUX, BORDEAUX, France)

### **Photocatalysis in Drug Discovery**

Dr Lisa CANDISH  
(BAYER, Wuppertal, Germany)

### **A Perspective on AI and Automation for the Medicinal Chemistry Lab**

Prof. Connor COLEY  
(MIT, Cambridge)

### **eIF2B Activators Beyond ISRIB: New Integrated Stress Response Inhibitors**

Dr Michael J. DART  
(ABBVIE, North Chicago, United States)

### **Discovery of ANT3310, a Novel Broad-Spectrum Serine $\beta$ -Lactamase Inhibitor of the Diazabicyclooctane Class, which strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter Baumannii**

Dr David DAVIES  
(ANTABIO SAS, Labège, France)

### **The Power and Pitfalls of Machine Learning in Early Stage Drug Discovery**

Prof. Charlotte DEANE  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

### **Novel Tetrazole Inhibitor of Mycobacterium Tuberculosis Tryptophan Synthase**

Dr Lourdes ENCINAS  
(GLAXOSMITHKLINE, Madrid, Spain)

### **EFMC-YMCS Prize 2021**

### **A Mating Mechanism to Generate Diversity for the Darwinian Selection of DNA-encoded Synthetic Molecules**

## Confirmed Speakers

Mr Lluç FARRERA SOLER  
(UNIVERSITY OF GENEVA, Geneva, Switzerland)

### **Targeting RNA with Small Molecules, A New Therapeutic Strategy**

Dr Yann FORICHER  
(SANOFI, Vitry-sur-Seine, France)

### **Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/Cyclin T1 for MYC-Dependent Cancers**

Dr David FREEMAN  
(KRONOS BIO, INC. , Massachussets, United States)

### **Leveraging Biomolecular Condensates for Drug Discovery**

Dr Marta FRIGOLE-VIVAS  
(DEWPOINT THERAPEUTICS GMBH, Dresden, Germany)

### **Title to be announced**

Prof. Tanja GAICH  
(UNIVERSITY OF KONSTANZ, Konstanz, Germany)

### **Enabling Technologies for Revealing Druggable Paths in RNA Biology**

Dr Amanda GARNER  
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

### **Title to be announced**

Prof. Matthew GAUNT  
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

### **Discovery of Covalent Protein Kinase Inhibitors**

Prof. Matthias GEHRINGER  
(UNIVERSITY OF TUEBINGEN, Tuebingen, Germany)

### **Searching for Drugs against Pandemic Viruses. A Case Study**

Dr Carmen GIL  
(CENTRO DE INVESTIGACIONES BIOLÓGICAS (CSIC), Madrid, Spain)

### **Automating Lead Optimisation with BRADSHAW**

Dr Darren GREEN  
(GSK, Stevenage, United Kingdom)

### **Covalent Fragment Approaches in Drug Discovery**

Prof. Gyorgy KESERU  
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

### **Attenuating Oncogenic Transcription with Small Molecules**

Prof. Angela KOEHLER  
(MIT KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH, Cambridge, United States)

### **Macrolide Inspired Macrocycles as Effective Disruptors of the IL-17A/IL-17RA Interaction**

Dr Sanja KOSTRUN  
(FIDELTA LTD, Zagreb, Croatia)

### **Inhibiting KRAS: Strategies, Structures, and Lessons Learned in the Invention of Sotorasib**

Dr Brian LANMAN  
(AMGEN, Thousand Oaks, CA, United States)

### **Antibody-Protac Conjugates: an Approach for Targeted Selective BRD4 Degradation in HER2+ Phenotypes**

## Confirmed Speakers

Dr María MANEIRO  
(UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, Santiago de Compostela, Spain)

### **Strategies to Discover Molecular Glue Degraders at Scale**

Dr Cristina MAYOR-RUIZ  
(IRB BARCELONA, Barcelona, Spain)

### **Next-level Chemical Tools for Ultrafast Bioorthogonal Bond-Cleavage Reactions**

Dr Hannes MIKULA  
(TU VIENNA, Vienna, Austria)

### **Late Stage Tritiation of Drug- and PET-Tracer-Candidates**

Dr Dieter MURI  
(ROCHE · PHARMA RESEARCH AND EARLY DEVELOPMENT (PRED), Basel, Switzerland)

### **The Phosphatase Family: a Widely Neglected Target Space for Small-Molecule Drug Discovery**

Dr Gerhard MÜLLER  
(ANAVO THERAPEUTICS, Heidelberg, Germany)

### **The discovery of the Clinical Candidate AZD0284, a Novel Orally Bioavailable Inverse Agonist of ROR $\gamma$ for the Treatment of Psoriasis**

Dr Frank NARJES  
(ASTRAZENECA, Mölndal, Sweden)

### **Disrupting hDot1L and MLL fusion protein interactions as a novel therapeutic strategy**

Prof. Zaneta NIKOLOVSKA-COLESKA  
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

### **Opportunity and Challenge of Artificial Intelligence (AI) in Drug Delivery**

Prof. Defang OUYANG  
(MACAU UNIVERSITY, Macau, China)

### **Chemical Probes and How to Find Them**

Dr Alex PAUTSCH  
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany)

### **De Novo Drug Design Using 3D Deep Generative Models**

Prof. Jianfeng PEI  
(PEKING UNIVERSITY, Beijing, China)

### **The Global Antibiotic R&D Partnership: Helping to Advance the Discovery & Development of New Treatments for Bacterial Infections**

Prof. Laura PIDDOCK  
(GLOBAL ANTIBIOTIC R&D PARTNERSHIP, Geneva, Switzerland)

### **New Opportunities for Studying the Function of the Nucleosome Remodeling Factor NURF Through Chemical Inhibition and Degradation**

Prof. William POMERANTZ  
(UNIVERSITY OF MINNESOTA, Minneapolis, United States)

### **Chemical Probes for Targets in Lipid Signalling**

Prof. Eugen PROSCHAK  
(GOETHE UNIVERSITY OF FRANKFURT, Frankfurt/Main, Germany)

### **EDELIRIS Keymical Space™ and GPCR : Identification of Allosteric Binders by AS-MS**

Dr Renaud PRUDENT  
(EDELIRIS, Lyon, France)

### **Tippling the Balance: MALT1 Inhibitors with Paradoxical Effects on the Immune System**

## Confirmed Speakers

Dr Jean QUANCARD  
(NOVARTIS, Basel, Switzerland)

### **Transcription Factors as Drug-Discovery Targets**

Prof. Fraydoon RASTINEJAD  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

### **Enzymatic Photocaging of Nucleic Acids: A Strategy for Controlling Methyltransferase Target Sites by Light**

Prof. Andrea RENTMEISTER  
(UNIVERSITY OF MÜNSTER, Münster, Germany)

#### **Title to be announced**

Dr Marc ROBILLARD  
(TAGWORKS PHARMACEUTICALS, Eindhoven, The Netherlands)

### **Big Data Analyses for the Discovery of Lead Structures from Nature**

Prof. Judith ROLLINGER  
(UNIVERSITY OF VIENNA, Vienna, Austria)

### **Design of Naturally Inspired Anti-Cancer Compounds that Modulate Cholesterol Homeostasis**

Dr Fanny ROUSSI  
(ICSN - CNRS, Gif sur Yvette, France)

### **New Aspects in DNA-encoded Chemical Library Construction and Screening**

Dr Jörg SCHEUERMANN  
(ETH ZÜRICH, Zürich, Switzerland)

### **Radiotheragnostics from Bench-to-Bedside**

Prof. Roger SCHIBLI  
(ETH ZÜRICH, Zürich, Switzerland)

#### **Title to be announced**

Prof. Wenqing SHU  
(SHANGHAITECH UNIVERSITY, Shanghai, China)

### **Targeting Protein-Protein Interactions of Receptor Complexes**

Prof. Kristian STROMGAARD  
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

#### **Title to be announced**

Dr Nicolas THOMÄ  
(FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

#### **Title to be announced**

Prof. Guy VAN DEN MOOTER  
(KULEUVEN, Leuven, Belgium)

### **High Throughput Affinity Screening for Rapid Hit Discovery and Prosecuting Intractable Targets**

Mr Jarrod WALSH  
(ASTRAZENECA, Macclesfield, United Kingdom)

### **Exploring Alternative Targets and Development of Precision Medicine Tools for CNS Diseases**

Prof. Daniel Martin WATTERSON  
(NORTHWESTERN UNIVERSITY, Chicago, United States)

#### **Title to be announced**

## Confirmed Speakers

Prof. Feng ZHU  
(ZHEJIANG UNIVERSITY, Hangzhou, China)

### Oral Communication

#### Chemical Modification of Wild-type Proteins

Dr Bauke ALBADA  
(WUR, Wageningen, The Netherlands)

#### Antidotes for Diseases: Chemistry and Biology Match Together to Tackle Epigenetics

Dr Paola B. ARIMONDO  
(INSTITUT PASTEUR - CNRS, Paris, France)

#### Visible-light Photocatalysis: a Powerful Tool in the Pursuit of New Pharmaceuticals

Dr Giulia BERGONZINI  
(ASTRAZENECA, Molndal, Sweden)

#### Discovery of Pseudomonas Aeruginosa Elastase LasB Inhibitors by in Situ Click Chemistry

Dr Virgyl CAMBERLEIN  
(HIPS - HELMHOLTZ-INSTITUT FÜR PHARMAZEUTISCHE FORSCHUNG SAARLAND, Saarbrücken, Germany)

#### Discovery of Clinical Candidate CHF-6366: a Super-soft Heterobifunctional Muscarinic Antagonist and $\beta_2$ -adrenoceptor Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Ms Laura CARZANIGA  
(CHIESI FARMACEUTICI SPA, PARMA, Italy)

#### Tuning the Reactivity of the Natural Product Andrographolide: Towards Targeted Covalent Inhibitors for the Treatment of Inflammation

Prof. Christina CHAI  
(NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore)

#### First Selective Nanomolar Inhibitors of ERAP2 for Modulation of the Antigen Presentation

Prof. Rebecca DEPREZ-POULAIN  
(UNIVERSITY OF LILLE / INSTITUT PASTEUR OF LILLE, Lille, France)

#### Molecular Glues for the 14-3-3 Interactome

Dr Richard DOVESTON  
(UNIVERSITY OF LEICESTER, Leicester, United Kingdom)

#### In Silico Prediction of Brain Penetration - High Accuracy Achieved

Dr Herve GENESTE  
(ABBVIE, Ludwigshafen, Germany)

#### NR2F6 Antagonists: in Vitro Pharmacology and Preclinical Data of a Potential Next Generation Immuno-oncology Therapy

Dr Francesco GRECO  
(TES PHARMA SRL, Perugia, Italy)

#### Structure-Guided Design of Foldamer-Based Inhibitors of Protein-Protein Interactions

Dr Gilles GUICHARD  
(CBMN & IECB, UNIVERSITY OF BORDEAUX, CNRS, BORDEAUX INP, Pessac, France)

#### Discovery And Profiling of AZ-6421: an Oral ER $\alpha$ -Protac with an in vitro-in vivo Disconnect

Dr Thomas HAYHOW  
(ASTRAZENECA, Cambridge, United Kingdom)

#### Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106

## Confirmed Speakers

Dr Timo HEINRICH  
(MERCK, DARMSTADT, Germany)

### **Photoactivated Covalent Capture of DNA-encoded Fragments to Identify Ligands for Challenging Targets**

Prof. Roderick HUBBARD  
(VERNALIS, Cambridge, United Kingdom)

### **Discovery of JNJ-1245, a Novel and Potent Fluoroallylamide Mcl-1 Inhibitor for the Treatment of Hematologic Malignancies**

Dr Soufyan JERHAOUI  
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium)

### **Identification and Structure-activity Relationship Profiling of Positive Allosteric Modulators Targeting Muscarinic Acetylcholine Receptors**

Dr Manuela JORG  
(MONASH UNIVERSITY, Parkville, Australia)

### **Development of First PET Tracers for the Imaging of CD73 Expression in Triple-negative Breast Cancer**

Dr Anna JUNKER  
(EUROPEAN INSTITUTE FOR MOLECULAR IMAGING, Muenster, Germany)

### **Dual Inhibition of P53-MDM2/4 Interactions With Spiropyrazoline Oxindoles**

Ms Elizabeth A. LOPES  
(FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisboa, Portugal)

### **Exploiting DNA-encoded Library Technology for the Discovery of Novel Antibody Recruiting Molecules Against LOX-1**

Ms Katherine MACFARLANE  
(UNIVERSITY OF STRATHCLYDE, London, United Kingdom)

### **Modulation of TDP-43-pathway by Brain Penetrant Protein Kinase Inhibitors, a New Hope for ALS and Related Disorders**

Prof. Ana MARTINEZ  
(CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain)

### **Mining the Leishmania Kinome**

Dr Exequiel PORTA  
(DURHAM UNIVERSITY, Durham, United Kingdom)

### **Human Dihydroorotate Dehydrogenase Inhibitor MEDS443: a Magic Bullet Against Coronaviruses**

Dr Stefano SAINAS  
(UNIVERSITY OF TORINO, Torino, Italy)

### **Using AI to Derive Valuable Insights from Drug Discovery Data**

Dr Matthew SEGALL  
(OPTIBRIUM, Cambridge, United Kingdom)

### **Bis-3-chloropiperidines Targeting TAR RNA as a Novel Strategy to Impair the HIV-1 Nucleocapsid Protein**

Dr Alice SOSIC  
(UNIVERSITY OF PADOVA, Padova, Italy)

### **Fast Detection and Imaging of Hydrogen Peroxide with New Borinic Probes**

Dr Boris VAUZEILLES  
(INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES, Gif-sur-Yvette, France)

### **A New Dual Mode of Action to Treat Pain - From Scratch to Pre-Clinical Candidate**

## Confirmed Speakers

Dr Anita WEGERT  
(SYMERES, Nijmegen, The Netherlands)

### **Iridium-catalyzed C-H Activation Methods for Late-stage Functionalization of Pharmaceuticals**

Dr Erik WEIS  
(ASTRAZENECA, Mölndal, Sweden)

### **Discovery of Novel Covalent, EGFR WT Sparing, HER2 Selective Inhibitors for the Treatment of Her2 Exon 20 Insertion Driven Tumours**

Dr Birgit WILDING  
(BOEHRINGER INGELHEIM, Vienna, Austria)

## First Time Disclosures

### **Discovery and Optimisation of Potent, Slow-dissociating Inhaled PI4KB Inhibitors**

Dr Sophie BERTRAND  
(GSK, Stevenage, United Kingdom)

### **Discovery of AZD5462, an Oral Agonist of the Relaxin Family Peptide Receptor 1 (RXFP1) for the Treatment of Cardiorenal Disease**

Dr Kenneth GRANBERG  
(ASTRAZENECA, Mölndal, Sweden)

### **First Disclosure of Cannabinoid Receptor Type 2 Agonist Rg7774 – An Innovative Oral Treatment for Diabetic Retinopathy**

Dr Uwe GREETHER  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

### **Discovery of BI 456906, a Novel Long-acting GCG/GLP-1 Receptor Dual Agonist for the Treatment of Patients With Obesity**

Dr Peter HAEBEL  
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach Riss, Germany)

### **MPGES1 Inhibitors: First Time Disclosure of Clinical Candidate BI01029539 / GS-248**

Dr Roland PFAU  
(BOEHRINGER INGELHEIM PHARMA GMBH&CO. KG, Ingelheim am Rhein, Germany)

### **First-time Disclosure of M1069, a Highly Selective Dual Inhibitor of Adenosine A<sub>2a</sub>/A<sub>2b</sub> Receptors With Improved Therapeutic Activity Compared to A<sub>2a</sub> Receptor Selective Antagonists**

Dr Kai SCHIEMANN  
(MERCK HEALTHCARE KGAA, Darmstadt, Germany)

## **EFMC Prizes for Young Medicinal Chemist or Chemical Biologist in Academia and in Industry Ceremony & Lectures**